Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06872359

Evaluation of Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling

Prospective, Multicentric, Open Label Clinical Investigation to Evaluate Performance and Safety of Injectable KIO017 Device Range for Facial Tissue Filling

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
210 (estimated)
Sponsor
Kiomed Pharma · Industry
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

The goal of this clinical trial is to primarily evaluate the performance of KIO017 in filling/volumizing after injection in different areas in healthy women or men, older than 18 years and seeking an improvement of her/his face aspect with resorbable filler. The main questions it aims to answer are: If the products are safe \- Acceptable local tolerance, with acceptable clinical signs after injection. If the clinical performance is as intended compared to baseline * Evaluation of performance by assessing the improvement of the appearance of the defect to be corrected by using Global Aesthetic Improvement Scale (GAIS) * Quantification of the improvement using the appropriate scale when available or other appropriates tool (angle for chin, for instance). * Pain felt during injection and after injection * Subject satisfaction

Conditions

Interventions

TypeNameDescription
DEVICEKIO017-1Subcutaneous and/or supraperiostal injections in chin and/or mid-face and/or jawline. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
DEVICEKIO017-2Subcutaneous injections in temples and/or nasolabial folds and/or marionette lines and/or mid-face. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.
DEVICEKIO017-3Injections in or around labial mucosa for lip volume and contour and/or intradermal injections in perioral lines. One (1) injection session on D0 and one (1) touch-up session on M1. The total volume injected per face and per session will not exceed 8 ml.

Timeline

Start date
2025-03-25
Primary completion
2025-12-01
Completion
2027-09-01
First posted
2025-03-12
Last updated
2025-09-08

Locations

3 sites across 2 countries: France, Poland

Source: ClinicalTrials.gov record NCT06872359. Inclusion in this directory is not an endorsement.